Literature DB >> 10454259

Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers.

M Watanabe1, K Fukutome, H Kato, M Murata, J Kawamura, T Shiraishi, R Yatani.   

Abstract

The c-met proto-oncogene encoding the receptor for the hepatocyte growth factor is expressed in several cancers. In the present study, c-met protein (c-Met) was detected in eight of 22 (36%) cases of prostatic intraepithelial neoplasia (PIN), five of 15 (33%) latent and 17 of 21 (81%) clinical prostate cancers, including seven metastatic lesions, using an immunohistochemical method. All seven (100%) metastatic lesions investigated demonstrated strong staining, and a correlation between c-Met expression and histology was observed. These results suggest a significant relationship between c-Met expression and progression of prostate neoplasms, including latent cancers.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10454259     DOI： 10.1016/s0304-3835(99)00102-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  9 in total

1.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

2.  Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.

Authors:  G A Gmyrek; M Walburg; C P Webb; H M Yu; X You; E D Vaughan; G F Vande Woude; B S Knudsen
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.

Authors:  Joseph Aldahl; Jiaqi Mi; Ariana Pineda; Won Kyung Kim; Adam Olson; Erika Hooker; Yongfeng He; Eun-Jeong Yu; Vien Le; Dong-Hoon Lee; Joseph Geradts; Zijie Sun
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

Review 4.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

5.  Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.

Authors:  Amanda Tate; Shuji Isotani; Michael J Bradley; Robert A Sikes; Rodney Davis; Leland W K Chung; Magnus Edlund
Journal:  BMC Cancer       Date:  2006-07-25       Impact factor: 4.430

Review 6.  Differential proteomic alterations between localised and metastatic prostate cancer.

Authors:  B S Taylor; S Varambally; A M Chinnaiyan
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

Review 7.  Met in urological cancers.

Authors:  Yasuyoshi Miyata; Akihiro Asai; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

8.  Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.

Authors:  Deborah R Kaye; Peter A Pinto; Fabiola Cecchi; Joseph Reilly; Alice Semerjian; Daniel C Rabe; Gopal Gupta; Peter L Choyke; Donald P Bottaro
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

9.  High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer.

Authors:  Frank Jacobsen; Sharad Nouraie Ashtiani; Pierre Tennstedt; Hans Heinzer; Ronald Simon; Guido Sauter; Hüseyin Sirma; Maria Christina Tsourlakis; Sarah Minner; Thorsten Schlomm; Uwe Michl
Journal:  Exp Ther Med       Date:  2012-10-25       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.